PetMed Express Q3 net sales $53M; Adj. EBITDA rises to $2M from $0.9M

PETMED EXPRESS INC

2025-Q3 EPS reported $0.26 revenue$180,506,000

Net sales of $53.0 million in Q3 fiscal 2025.
Gross margin rate 28.1%, up 80 bps from prior year.
Adjusted EBITDA $2.0 million vs. $0.9 million prior year, a $1.1M improvement.
G&A expenses reduced by $2.6 million year-over-year.
CEO highlights transformation progress and operational efficiency.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.